Beta Bionics CFO sells 10,000 shares after option exercise
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell pattern in Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported an exercise-and-sell pattern in Common Stock. He exercised stock options covering 9,878 shares at an exercise price of $5.10 per share and sold 10,000 shares in open-market transactions at weighted average prices around $17.04 on June 26, 2026 and June 29, 2026. The sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 15, 2025. Following these transactions, he directly holds 165,931 shares of Common Stock, indicating he retained a large majority of his equity position.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
6 txns
Insider
Feider Stephen
Role
Chief Financial Officer
Sold
10,000 shs ($170K)
Approx. gross sale proceeds
$170K
Approx. exercise cost
$50K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 4,896 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,896 | $5.10 | $25K |
| Sale | Common Stock | 4,896 | $17.0304 | $83K |
| Exercise | Employee Stock Option (right to buy) | 4,982 | $0.00 | $0.00 |
| Exercise | Common Stock | 4,982 | $5.10 | $25K |
| Sale | Common Stock | 5,104 | $17.0467 | $87K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 39,817 contracts (Direct);
Common Stock — 165,931 shares (Direct)
Footnotes (4)
- F1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025.
- F2. The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F3. The weighted average sale price for the transaction reported was $17.0304 and the range of prices were between $17 and $17.08. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- F4. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.
Key Figures
Shares sold: 10,000 shares
Weighted average sale price 6/26/2026: $17.046782/share
Weighted average sale price 6/29/2026: $17.0304/share
+5 more
8 metrics
Shares sold
10,000 shares
Total Common Stock sold in open-market transactions
Weighted average sale price 6/26/2026
$17.046782/share
Common Stock sales on June 26, 2026
Weighted average sale price 6/29/2026
$17.0304/share
Common Stock sales on June 29, 2026
Options exercised
9,878 shares
Employee stock options converted to Common Stock
Option exercise price
$5.10/share
Employee Stock Option (right to buy) exercise price
Shares owned after transactions
165,931 shares
Direct Common Stock ownership following transactions
10b5-1 plan adoption date
May 15, 2025
Plan governing pre-arranged sales
Option expiration
September 13, 2033
Expiration date for the reported employee stock options
Key Terms
Rule 10b5-1 Plan, Employee Stock Option (right to buy), weighted average sale price, derivative security, +1 more
5 terms
Rule 10b5-1 Plan regulatory
"Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 15, 2025."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
Employee Stock Option (right to buy) financial
"security_title: Employee Stock Option (right to buy)"
weighted average sale price financial
"The weighted average sale price for the transaction reported was $17.046782 and the range of prices were between $17 and $17.12."
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
Common Stock financial
"security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Beta Bionics (BBNX) CFO Stephen Feider report in this Form 4?
He reported exercising stock options and selling shares of Beta Bionics Common Stock. The filing shows coordinated option exercises and open-market sales over two days, while retaining a substantial remaining direct share position after the transactions.
What stock options did the Beta Bionics (BBNX) CFO exercise?
He exercised employee stock options for 9,878 shares of Common Stock. These options carried an exercise price of $5.10 per share and were part of a grant that vests in 48 equal monthly installments beginning September 14, 2023, according to the disclosure.
Were the Beta Bionics (BBNX) CFO’s stock sales pre-planned?
Yes. The filing states that the shares sold were pursuant to a Rule 10b5-1 trading plan adopted on May 15, 2025. Such plans pre-schedule trades, indicating the timing of these sales was arranged in advance rather than decided spontaneously.
What is the significance of the weighted average sale prices disclosed for BBNX?
The filing provides weighted average prices and price ranges for the sales, such as $17.046782 between $17 and $17.12. This detail helps investors understand the execution levels, and the filer offers to provide full breakdowns upon request to the company or SEC staff.
AI-generated analysis. How Rhea-AI works. Not financial advice.
